Journal article
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for adults with chronic kidney disease: a clinical practice guideline
Abstract
CLINICAL QUESTION: What is the impact of sodium-glucose cotransporter-2 (SGLT-2) inhibitors on survival and on cardiovascular and kidneyoutcomes for adults living with chronic kidney disease (CKD)?
CURRENT PRACTICE: Few therapies slow kidney disease progression and improve long term prognosis for adults living with CKD. SGLT-2 inhibitors have demonstrated cardiovascular and kidney benefits in adults with CKD with and without type 2 diabetes. …
Authors
Agarwal A; Zeng X; Li S; Rayner D; Foroutan F; Aertgeerts B; Coyac F; Farhoumand PD; Demaine A; Heen AF
Journal
The BMJ, Vol. 387, ,
Publisher
BMJ
DOI
10.1136/bmj-2024-080257
ISSN
0959-8138